From the King Kong of weight-loss jabs to the Godzilla of the category, the GLP-1 industry is undergoing big changes ...

Altimmune recently announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to pemvidutide, its balanced 1:1 glucagon/GLP-1 dual agonist, for treating metabolic ...

Glucagon-like peptide-1 receptor agonists (GLP-1s or GLP-1RAs) – also known as weight-loss jabs – are medicines that help ...

Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 ...

With weight loss drugs taking the world by storm, more people are exploring adding these medical marvels to their toolkits.

People who stop taking GLP-1 drugs such as Ozempic and Wegovy for weight loss are projected to regain their shed pounds ...

The American Diabetes Association has released its annual update to ”Standards of Medical Care in Diabetes.” The document, published in Diabetes Care, includes all of the group's current clinical ...

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ("Amylyx" or the "Company") today announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development ...

A major study finds that weight loss drugs work while used, but weight and health benefits often return after stopping ...

Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity Advancing NA-931 into two Phase 3 programs as ...

When people who are overweight and obese stopped taking their weight-loss medications they regained weight faster than those ...